{
  "outcomes_metadata": {
    "timestamp": "2025-10-02T17:13:23.221186",
    "indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
    "consolidation_type": "outcomes",
    "data_split": "test",
    "total_unique_outcomes": 54,
    "source_countries": [
      "DE",
      "DK",
      "EN",
      "EU",
      "FR",
      "PT",
      "SE"
    ],
    "source_types": [
      "clinical_guideline",
      "hta_submission"
    ]
  },
  "consolidated_outcomes": {
    "efficacy": {
      "survival_endpoints": [
        "overall survival (OS)",
        "progression-free survival (PFS; RECIST 1.1)",
        "progression-free survival (PFS; RECIST v1.1)",
        "progression-free survival (independent review panel, RECIST 1.1)",
        "progression-free survival (PFS)",
        "event-free survival",
        "time to progression",
        "time to next treatment",
        "duration of treatment",
        "survival"
      ],
      "response_measures": [
        "objective response rate (ORR; RECIST 1.1, blinded independent central review)",
        "objective response rate (ORR; RECIST 1.1)",
        "objective response rate (ORR)",
        "overall response rate",
        "response rates",
        "complete response (RECIST 1.1)",
        "partial response (RECIST 1.1)",
        "duration of response (DoR; RECIST 1.1)",
        "duration of response (DoR)",
        "disease control rate (complete, partial, or stable disease for at least 5 weeks)",
        "disease control rate",
        "time to response (from treatment initiation to first complete or partial response)",
        "time to response"
      ],
      "progression_measures": [
        "time to symptom deterioration",
        "symptom control"
      ]
    },
    "safety": {
      "adverse_events": [
        "adverse events (general)",
        "adverse events (CTCAE v5.0)",
        "adverse events (CTCAE v4.03)",
        "adverse events (Common Terminology Criteria for Adverse Events, CTCAE v5.0)",
        "adverse events (grade 3 or higher)",
        "adverse events (grade 3-4)",
        "side effects (PRO-CTCAE instrument)",
        "serious side effects on the skin",
        "interstitial lung disease (severe adverse event)",
        "liver disorders (severe adverse event)",
        "stomatitis (adverse event)",
        "peripheral oedema (adverse event)",
        "peripheral neuropathy (adverse event)",
        "alopecia (adverse event)",
        "blood and lymphatic system disorders (adverse event)",
        "fatigue (adverse event)",
        "fatigue",
        "fever (adverse event)",
        "fever",
        "infections and infestations (adverse event)",
        "diarrhoea",
        "alanine aminotransferase increase",
        "aspartate aminotransferase increase",
        "neutropenia",
        "febrile neutropenia",
        "mortality-related toxicity"
      ],
      "serious_events": [
        "serious adverse events (SAEs)",
        "serious adverse events",
        "serious adverse events (grade 3-4)",
        "fatalities"
      ],
      "discontinuations": [
        "discontinuation due to adverse events",
        "treatment discontinuation due to adverse events (CTCAE v5.0)",
        "treatment discontinuation due to adverse events (CTCAE v4.03)",
        "dropout rate"
      ]
    },
    "quality_of_life": {
      "patient_reported_outcomes": [
        "EORTC QLQ-C30",
        "EORTC QLQ-LC13",
        "BPI-SF",
        "FACT-G GP5",
        "PGI-C",
        "PGIS",
        "NSCLC-SAQ",
        "PRO-CTCAE",
        "EQ-5D-5L",
        "EQ-5D visual analogue scale (EQ-5D VAS)",
        "visual analogue scale (utility measurement)",
        "health-related quality of life (EORTC QLQ-C30 functional scales)",
        "health-related quality of life (measured by time to death)"
      ],
      "functional_status": [
        "health status (EORTC QLQ-C30)",
        "health status (EORTC QLQ-LC13)",
        "health status (BPI-SF)",
        "health status (FACT-G GP5)",
        "health status (PGI-C)",
        "preservation of quality of life"
      ],
      "symptom_measures": [
        "symptomatology (EORTC QLQ-C30)",
        "symptomatology (EORTC QLQ-LC13)",
        "symptomatology (BPI-SF)",
        "symptomatology (FACT-G GP5)",
        "symptomatology (PGI-C)"
      ]
    },
    "economic": {
      "cost_effectiveness": [
        "cost-effectiveness (incremental cost-effectiveness ratio, ICER)",
        "cost-effectiveness (cost per QALY)"
      ],
      "utilities": [
        "quality-adjusted life years (QALYs)",
        "utility decrement per cycle (treatment-related disutility)"
      ],
      "resource_utilization": [
        "duration of treatment"
      ]
    },
    "other": {
      "exploratory_endpoints": [],
      "biomarkers": []
    }
  }
}